SavedAdd your journal

Journals / Eskisehir Medical Journal / 2026 / Volume: 7 Issue: 1

Multiple Sclerosis in Older Adults: Epidemiology, Pathophysiology, Clinical Features, and Treatment Considerations

Emrah Emre Deveci(Muğla Sıtkı Koçman Üniversitesi Tıp Fakültesi, Nöroloji Anabilim Dalı; Muğla Sıtkı Koçman Üniversitesi Sağlık Bilimleri Enstitüsü, Yaşlı Sağlığı Doktora Programı)0000-0001-9280-3297
Yeşim Beckmann(İzmir Kâtip Çelebi Üniversitesi Tıp Fakültesi, Nöroloji Anabilim Dalı)0000-0001-5158-8834
Pages
—
Publication Date
2026-02-24
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Increasing research efforts in older adults with multiple sclerosis may enhance clinicians’ understanding and improve the effectiveness of treatment strategies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Although multiple sclerosis predominantly affects young adults, recent advances in diagnostic methods and therapeutic strategies have led to an increasing recognition of the disease in older adults.
📊
Key Findings & Data:This narrative review synthesizes evidence published between 2000 and 2025 on the epidemiology, age-related pathophysiological mechanisms, clinical course, and therapeutic considerations of multiple sclerosis in older adults, based on findings retrieved from PubMed, Scopus, and Web of Science, to support age-adapted clinical decision-making.
💡
Conclusion & Impact:Increasing research efforts in older adults with multiple sclerosis may enhance clinicians’ understanding and improve the effectiveness of treatment strategies.
🔬Design:Review & Systematic Survey
📍Scope:2000 Verileri
⚙️Variables:Demyelination · senescent cells · biological age

Abstract

Although multiple sclerosis predominantly affects young adults, recent advances in diagnostic methods and therapeutic strategies have led to an increasing recognition of the disease in older adults. Aging induces distinct pathophysiological, clinical, and radiological changes in patients with multiple sclerosis, and management in this population requires a tailored approach due to comorbidities and age-related differences in treatment response. This narrative review synthesizes evidence published between 2000 and 2025 on the epidemiology, age-related pathophysiological mechanisms, clinical course, and therapeutic considerations of multiple sclerosis in older adults, based on findings retrieved from PubMed, Scopus, and Web of Science, to support age-adapted clinical decision-making. The reviewed literature indicates a growing prevalence of multiple sclerosis in older adults across diverse geographic regions. With advancing age, disability accumulation and disease progression independent of relapse activity become more prominent than inflammatory relapse-related activity, and age-associated impairment of remyelination is thought to contribute significantly to this process. The limited number of clinical studies specifically focusing on this population highlights an important unmet need in the field. Increasing research efforts in older adults with multiple sclerosis may enhance clinicians’ understanding and improve the effectiveness of treatment strategies.

🔖

Cite This Article

Deveci, E. E., Beckmann, Y. (2026). Multiple Sclerosis in Older Adults: Epidemiology, Pathophysiology, Clinical Features, and Treatment Considerations. Eskisehir Medical Journal, Volume: 7 Issue: 1. https://doi.org/10.48176/esmj.2026.246

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (76)

  1. Filippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Primers 2018;4(1):43. doi:10.1038/s41572-018-0041-4.
  2. Marrie RA, Yu N, Blanchard J, Leung S, Elliott L. The rising prevalence and changing age distribution of multiple sclerosis in Manitoba. Neurology 2010;74(6):465-71. doi:10.1212/WNL.0b013e3181cf6ec0.
  3. Li J, Hutton GJ, Aparasu RR. Prevalence of multiple sclerosis and disease-modifying therapy use in older adults in the United States, 2011–2021. Mult Scler 2025;31(13):1595-99. doi:10.1177/13524585251368687.
  4. Prosperini L, Lucchini M, Ruggieri S, et al. Shift of multiple sclerosis onset towards older age. J Neurol Neurosurg Psychiatry 2022;93(10):1137-9. doi:10.1136/jnnp-2022-329049.
  5. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014;83(3):278-86. doi:10.1212/WNL.0000000000000560.
  6. Wallin MT, Culpepper WJ, Campbell JD, et al.; US Multiple Sclerosis Prevalence Workgroup. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology 2019;92(10):e1029-40. doi:10.1212/WNL.0000000000007035.
  7. Hittle M, Culpepper WJ, Langer-Gould A, et al. Population-based estimates for the prevalence of multiple sclerosis in the United States by race, ethnicity, age, sex, and geographic region. JAMA Neurol 2023;80(7):693-701. doi:10.1001/jamaneurol.2023.1135.
  8. Ahlgren C, Odén A, Lycke J. High nationwide prevalence of multiple sclerosis in Sweden. Mult Scler 2011;17(8):901-8. doi:10.1177/1352458511403794.
  9. Amankwah N, Marrie RA, Bancej C, et al. Multiple sclerosis in Canada 2011 to 2031: results of a microsimulation modelling study of epidemiological and economic impacts. Health Promot Chronic Dis Prev Can 2017;37(2):37-48. doi:10.24095/hpcdp.37.2.02.
  10. Koch-Henriksen N, Thygesen LC, Stenager E, Laursen B, Magyari M. Incidence of MS has increased markedly over six decades in Denmark particularly with late onset and in women. Neurology 2018;90(22):e1954-63. doi:10.1212/WNL.0000000000005612.
  11. Koch-Henriksen N, Magyari M. Apparent changes in the epidemiology and severity of multiple sclerosis. Nat Rev Neurol 2021;17(11):676-88. doi:10.1038/s41582-021-00556-y.
  12. Vaughn CB, Jakimovski D, Kavak KS, et al. Epidemiology and treatment of multiple sclerosis in elderly populations. Nat Rev Neurol 2019;15(6):329-42. doi:10.1038/s41582-019-0183-3.
  13. Sanai SA, Saini V, Benedict RH, et al. Aging and multiple sclerosis. Mult Scler 2016;22(6):717-25. doi:10.1177/1352458516634871.
  14. Graves JS, Krysko KM, Hua LH, Absinta M, Franklin RJM, Segal BM. Ageing and multiple sclerosis. Lancet Neurol 2023;22(1):66-77. doi:10.1016/S1474-4422(22)00184-3.
  15. Mirmosayyeb O, Brand S, Barzegar M, et al. Clinical characteristics and disability progression of early- and late-onset multiple sclerosis compared to adult-onset multiple sclerosis. J Clin Med 2020;9(5):1326. doi:10.3390/jcm9051326.
  16. Bermel RA, Rae-Grant AD, Fox RJ. Diagnosing multiple sclerosis at a later age: more than just progressive myelopathy. Mult Scler 2010;16(11):1335-40. doi:10.1177/1352458510377334.
  17. Franklin RJM, Ffrench-Constant C. Regenerating CNS myelin—from mechanisms to experimental medicines. Nat Rev Neurosci 2017;18(12):753-69. doi:10.1038/nrn.2017.136.
  18. Franklin RJM, Frisén J, Lyons DA. Revisiting remyelination: towards a consensus on the regeneration of CNS myelin. Semin Cell Dev Biol 2021;116:3-9. doi:10.1016/j.semcdb.2020.09.009.
  19. Sim FJ, Zhao C, Penderis J, Franklin RJ. The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. J Neurosci 2002;22(7):2451-9. doi:10.1523/JNEUROSCI.22-07-02451.2002.
  20. Neumann B, Baror R, Zhao C, et al. Metformin restores CNS remyelination capacity by rejuvenating aged stem cells. Cell Stem Cell 2019;25(4):473-85.e8. doi:10.1016/j.stem.2019.08.015.
  21. Willis CM, Nicaise AM, Bongarzone ER, et al. Astrocyte support for oligodendrocyte differentiation can be conveyed via extracellular vesicles but diminishes with age. Sci Rep 2020;10(1):828. doi:10.1038/s41598-020-57663-x.
  22. Goldschmidt T, Antel J, König FB, Brück W, Kuhlmann T. Remyelination capacity of the MS brain decreases with disease chronicity. Neurology 2009;72(22):1914-21. doi:10.1212/WNL.0b013e3181a8260a.
  23. Heß K, Starost L, Kieran NW, et al. Lesion stage-dependent causes for impaired remyelination in MS. Acta Neuropathol 2020;140(3):359-75. doi:10.1007/s00401-020-02189-9.
  24. Bolton C, Smith PA. The influence and impact of ageing and immunosenescence (ISC) on adaptive immunity during multiple sclerosis (MS) and the animal counterpart experimental autoimmune encephalomyelitis (EAE). Ageing Res Rev 2018;41:64-81. doi:10.1016/j.arr.2017.10.005.
  25. Dema M, Eixarch H, Hervera A, et al. Disease aggravation with age in an experimental model of multiple sclerosis: role of immunosenescence. Aging Cell 2025;24(5):e14491. doi:10.1111/acel.14491.
  26. Fernández A, Quintana E, Velasco P, et al. Senescent accelerated prone 8 (SAMP8) mice as a model of age dependent neuroinflammation. J Neuroinflammation 2021;18(1):75. doi:10.1186/s12974-021-02104-3.
  27. Gyoneva S, Hosur R, Gosselin D, et al. Cx3cr1-deficient microglia exhibit a premature aging transcriptome. Life Sci Alliance 2019;2(6):e201900453. doi:10.26508/lsa.201900453.
  28. Norden DM, Godbout JP. Review: microglia of the aged brain: primed to be activated and resistant to regulation. Neuropathol Appl Neurobiol 2013;39(1):19-34. doi:10.1111/j.1365-2990.2012.01306.x.
  29. Thewissen M, Somers V, Venken K, et al. Analyses of immunosenescent markers in patients with autoimmune disease. Clin Immunol 2007;123(2):209-18. doi:10.1016/j.clim.2007.01.005.
  30. Callender LA, Carroll EC, Beal RWJ, et al. Human CD8+ EMRA T cells display a senescence-associated secretory phenotype regulated by p38 MAPK. Aging Cell 2018;17(1):e12675. doi:10.1111/acel.12675.
  31. Huber AK, Giles DA, Segal BM, Irani DN. An emerging role for eotaxins in neurodegenerative disease. Clin Immunol 2018;189:29-33. doi:10.1016/j.clim.2016.09.010.
  32. Parajuli B, Horiuchi H, Mizuno T, Takeuchi H, Suzumura A. CCL11 enhances excitotoxic neuronal death by producing reactive oxygen species in microglia. Glia 2015;63(12):2274-84. doi:10.1002/glia.22892.
  33. Bell L, Lenhart A, Rosenwald A, Monoranu CM, Berberich-Siebelt F. Lymphoid aggregates in the CNS of progressive multiple sclerosis patients lack regulatory T cells. Front Immunol 2020;10:3090. doi:10.3389/fimmu.2019.03090.
  34. Ruiz-Ruiz S, Sanchez-Carrillo S, Ciordia S, et al. Functional microbiome deficits associated with ageing: chronological age threshold. Aging Cell 2020;19(1):e13063. doi:10.1111/acel.13063.
  35. Salazar N, Arboleya S, Fernández-Navarro T, de Los Reyes-Gavilán CG, Gonzalez S, Gueimonde M. Age-associated changes in gut microbiota and dietary components related with the immune system in adulthood and old age: a cross-sectional study. Nutrients 2019;11(8):1765. doi:10.3390/nu11081765.
  36. Levine ME. Modeling the rate of senescence: can estimated biological age predict mortality more accurately than chronological age? J Gerontol A Biol Sci Med Sci 2013;68(6):667-74. doi:10.1093/gerona/gls233.
  37. Kular L, Klose D, Urdánoz-Casado A, et al. Epigenetic clock indicates accelerated aging in glial cells of progressive multiple sclerosis patients. Front Aging Neurosci 2022;14:926468. doi:10.3389/fnagi.2022.926468.
  38. Maltby V, Xavier A, Ewing E, et al. Evaluation of cell-specific epigenetic age acceleration in people with multiple sclerosis. Neurology 2023;101(7):e679-89. doi:10.1212/WNL.0000000000207489.
  39. Blackburn EH, Epel ES, Lin J. Human telomere biology: a contributory and interactive factor in aging, disease risks, and protection. Science 2015;350(6265):1193-8. doi:10.1126/science.aab3389.
  40. Krysko KM, Henry RG, Cree BAC, et al.; University of California, San Francisco MS-EPIC Team. Telomere length is associated with disability progression in multiple sclerosis. Ann Neurol 2019;86(5):671-82. doi:10.1002/ana.25592.
  41. Habib R, Ocklenburg S, Hoffjan S, Haghikia A, Epplen JT, Arning L. Association between shorter leukocyte telomeres and multiple sclerosis. J Neuroimmunol 2020;341:577187. doi:10.1016/j.jneuroim.2020.577187.
  42. Miner AE, Yang JH, Kinkel RP, Graves JS. The NHANES biological age index demonstrates accelerated aging in MS patients. Mult Scler Relat Disord 2023;77:104859. doi:10.1016/j.msard.2023.104859.
  43. Krysko KM, Graves JS, Dobson R, et al. Sex effects across the lifespan in women with multiple sclerosis. Ther Adv Neurol Disord 2020;13:1756286420936166. doi:10.1177/1756286420936166.
  44. Graves JS, Henry RG, Cree BAC, et al.; University of California, San Francisco MS-EPIC Team. Ovarian aging is associated with gray matter volume and disability in women with MS. Neurology 2018;90(3):e254-60. doi:10.1212/WNL.0000000000004843.
  45. Baroncini D, Annovazzi PO, De Rossi N, et al. Impact of natural menopause on multiple sclerosis: a multicentre study. J Neurol Neurosurg Psychiatry 2019;90(11):1201-6. doi:10.1136/jnnp-2019-320587.
  46. Bove R, Healy BC, Musallam A, Glanz BI, De Jager PL, Chitnis T. Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort. Mult Scler 2016;22(7):935-43. doi:10.1177/1352458515606211.
  47. Lunde HMB, Assmus J, Myhr KM, Bø L, Grytten N. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study. J Neurol Neurosurg Psychiatry 2017;88(8):621-25. doi:10.1136/jnnp-2016-315238.
  48. Naseri A, Nasiri E, Sahraian MA, Daneshvar S, Talebi M. Clinical features of late-onset multiple sclerosis: a systematic review and meta-analysis. Mult Scler Relat Disord 2021;50:102816. doi:10.1016/j.msard.2021.102816.
  49. Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry 2014;85(1):67-75. doi:10.1136/jnnp-2012-304333.
  50. Tutuncu M, Tang J, Zeid NA, et al. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler 2013;19(2):188-98. doi:10.1177/1352458512451510.
  51. Scalfari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA. Age and disability accumulation in multiple sclerosis. Neurology 2011;77(13):1246-52. doi:10.1212/WNL.0b013e318230a17d.
  52. Filippi M, Preziosa P, Barkhof F, et al. The ageing central nervous system in multiple sclerosis: the imaging perspective. Brain 2024;147(11):3665-80. doi:10.1093/brain/awae251.
  53. Müller J, Cagol A, Lorscheider J, et al. Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review. JAMA Neurol 2023;80(11):1232-45. doi:10.1001/jamaneurol.2023.3331.
  54. Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol 2020;77(9):1132-40. doi:10.1001/jamaneurol.2020.1568.
  55. Cree BAC, Hollenbach JA, Bove R, et al.; University of California, San Francisco MS-EPIC Team. Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol 2019;85(5):653-66. doi:10.1002/ana.25463.
  56. Capkun G, Dahlke F, Lahoz R, et al. Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: an observational study using the US Department of Defense administrative claims database. Mult Scler Relat Disord 2015;4(6):546-54. doi:10.1016/j.msard.2015.08.005.
  57. Manouchehrinia A, Tanasescu R, Tench CR, Constantinescu CS. Mortality in multiple sclerosis: meta-analysis of standardised mortality ratios. J Neurol Neurosurg Psychiatry 2016;87(3):324-31. doi:10.1136/jnnp-2015-310361.
  58. Brønnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004;127(4):844-50. doi:10.1093/brain/awh104.
  59. Marrie RA, Reider N, Cohen J, et al. A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. Mult Scler 2015;21(3):318-31. doi:10.1177/1352458514564485.
  60. Marrie RA, Elliott L, Marriott J, Cossoy M, Blanchard J, Leung S, Yu N. Effect of comorbidity on mortality in multiple sclerosis. Neurology 2015;85(3):240-7. doi:10.1212/WNL.0000000000001718.
  61. Wardlaw JM, Smith EE, Biessels GJ, et al.; STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013;12(8):822-38. doi:10.1016/S1474-4422(13)70124-8.
  62. Sastre-Garriga J, Pareto D, Battaglini M, et al.; MAGNIMS study group. MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. Nat Rev Neurol 2020;16(3):171-82. doi:10.1038/s41582-020-0314-x.
  63. Filippi M, Preziosa P, Langdon D, et al. Identifying progression in multiple sclerosis: new perspectives. Ann Neurol 2020;88(3):438-52. doi:10.1002/ana.25808.
  64. Absinta M, Sati P, Masuzzo F, et al. Association of chronic active multiple sclerosis lesions with disability in vivo. JAMA Neurol 2019;76(12):1474-83. doi:10.1001/jamaneurol.2019.2399.
  65. Montalban X, Lebrun-Frénay C, Oh J, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol 2025;24(10):850-65. doi:10.1016/S1474-4422(25)00270-4.
  66. Gafson AR, Jiang X, Shen C, et al. Serum neurofilament light and multiple sclerosis progression independent of acute inflammation. JAMA Netw Open 2022;5(2):e2147588. doi:10.1001/jamanetworkopen.2021.47588.
  67. Benkert P, Meier S, Schaedelin S, et al.; NfL Reference Database in the Swiss Multiple Sclerosis Cohort Study Group. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol 2022;21(3):246-57. doi:10.1016/S1474-4422(22)00009-6.
  68. Barro C, Healy BC, Liu Y, et al. Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2022;10(1):e200052. doi:10.1212/NXI.0000000000200052.
  69. Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 2010;74(13):1041-7. doi:10.1212/WNL.0b013e3181d6b125.
  70. Magyari M, Sorensen PS. Comorbidity in multiple sclerosis. Front Neurol 2020;11:851. doi:10.3389/fneur.2020.00851.
  71. Weideman AM, Tapia-Maltos MA, Johnson K, Greenwood M, Bielekova B. Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Front Neurol 2017;8:577. doi:10.3389/fneur.2017.00577.
  72. Montalban X, Hauser SL, Kappos L, et al.; ORATORIO Clinical Investigators. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017;376(3):209-20. doi:10.1056/NEJMoa1606468.
  73. Tettey P, Simpson S Jr, Taylor BV, van der Mei IA. Vascular comorbidities in the onset and progression of multiple sclerosis. J Neurol Sci 2014;347(1-2):23-33. doi:10.1016/j.jns.2014.10.020.
  74. Corboy JR, Fox RJ, Kister I, et al. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial. Lancet Neurol 2023;22(7):568-77. doi:10.1016/S1474-4422(23)00154-0.
  75. Scalfari A, Knappertz V, Cutter G, Goodin DS, Ashton R, Ebers GC. Mortality in patients with multiple sclerosis. Neurology 2013;81(2):184-92. doi:10.1212/WNL.0b013e31829a3388.
  76. Palladino R, Marrie RA, Majeed A, Chataway J. Evaluating the risk of macrovascular events and mortality among people with multiple sclerosis in England. JAMA Neurol 2020;77(7):820-28. doi:10.1001/jamaneurol.2020.0664.